Big Pharma’s steady double-digit price hikes cost Medicare billions

Tracy Staton

A new report from the Center for and Medicaid Services highlights some commonly used meds whose sales growth–and spending–depends more on rising prices than on rising demand.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS